Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think! opens in new tab/window

Elsevier
Publish with us
AI-Generated response:

How can I differentiate serotonin syndrome from neuroleptic malignant syndrome?

Answer generated on June 4, 2024

The AI-generated responses are for illustration purposes only and should not be used for medical purposes.

Serotonin syndrome typically presents rapidly after a change in medication and features neuromuscular hyperactivity such as hyperreflexia and myoclonus, while neuroleptic malignant syndrome develops more gradually, characterized by muscle rigidity and bradykinesia.[1-3]

  • Serotonin syndrome often develops within 24 hours of initiating or increasing a proserotonergic medication and may resolve quickly with appropriate management.[1]

  • Neuroleptic malignant syndrome usually progresses over days to weeks and is associated with the use of antipsychotic medications or withdrawal of dopamine agonists.[2]

  • Key symptoms of serotonin syndrome include agitation, diaphoresis, diarrhea, tremor, and hyperthermia, along with neuromuscular hyperactivity (hyperreflexia, myoclonus).[1]

  • Neuroleptic malignant syndrome is marked by severe muscle rigidity, altered mental status, autonomic instability, and hyperthermia, with symptoms resolving more slowly, typically over a week to ten days.[2]

  • Diagnostic criteria for serotonin syndrome include recent addition or increase of a proserotonergic agent and the presence of symptoms such as hyperreflexia and myoclonus, without recent addition or increase in dose of a neuroleptic agent.[1]

Additional info

Differentiating serotonin syndrome from neuroleptic malignant syndrome is crucial due to their differing treatments and potential complications. Serotonin syndrome requires immediate cessation of serotonergic drugs and may involve symptomatic care with agents like cyproheptadine, while neuroleptic malignant syndrome necessitates stopping the offending neuroleptic drug and managing symptoms, potentially with medications like dantrolene or bromocriptine to address muscle rigidity and metabolic abnormalities.[1-2] Understanding the onset and specific symptomatology associated with each condition, as well as a detailed medication history, is essential for accurate diagnosis and appropriate management.

References

Reference 1

1.

Elsevier ClinicalKey Derived Clinical Overview

• Medical: Neuroleptic malignant syndrome, malignant hyperthermia, infection (e.g., meningitis, encephalitis), hyperthyroidism, tetanus., • Toxins: Anticholinergic, amphetamines, cocaine, lithium, LSD, PCP, salicylates. • Classic features in differentiation of NMS from SS are that SS develops over 24 h, involves neuromuscular hyperactivity (hyperreflexia, myoclonus), and begins to resolve within 24 h with appropriate therapy, whereas NMS develops gradually over days to weeks, involves sluggish neuromuscular response, and resolves over an average period of 1 wk to 10 days.

• SS is a clinical diagnosis. There are no specific laboratory tests for SS. A high index of suspicion along with a detailed medication history is the mainstay of diagnosis. • Diagnostic criteria: Most accurate is Hunter Serotonin Toxicity Criteria (sensitivity 84%, specificity 97%, confirmation by toxicologist). Sternbach diagnostic criteria (Table E1) are also commonly used with statistics of sensitivity 75% and specificity 96%. 1.000000000000000e+00 Recent addition or increase of proserotonergic medication 2.000000000000000e+00 At least three of the following: • Agitation • Ataxia • Diaphoresis • Diarrhea • Hyperreflexia • Hyperthermia • Mental status changes • Myoclonus • Shivering • Tremor 3.000000000000000e+00 Neuroleptic agent not added or dose increased before the onset of symptoms 4.000000000000000e+00 Diagnosis of infections, withdrawal, and other poisoning or metabolic disruptions excluded

Reference 2

2.

Elsevier ClinicalKey Derived Clinical Overview

• Neuropsychiatric: Catatonia, acute psychosis with agitation, status epilepticus, Parkinsonism • Table E2summarizes the differential diagnosis of neuroleptic malignant syndrome TABLE E2Differential Diagnosis of Neuroleptic Malignant SyndromeDisease∗Pathologic MechanismDifferentiating FactorTime CourseTreatmentNeuroleptic malignant syndromeImpaired thermoregulation in hypothalamus and basal ganglia due to relative lack of dopamine activityAntipsychotic medication use, muscle rigidityGradual, progresses over several daysStop offending medicationHydrationActive coolingIntravenous benzodiazepines to relax muscles and control agitationNeuromuscular blockade (nondepolarizing agents)ControversialBromocriptine or amantadineDantroleneSerotonin syndromeExcess serotonin and dopamine levels in central nervous systemMedications (usually a combination) that increase serotonin levels (e.g., SSRIs, MAOIs, dextromethorphan, lithium, meperidine, tramadol, tryptophan); muscle rigidityUsually rapid after introduction of new medication or increase in dose; can be gradualStop offending medicationHydrationActive coolingCyproheptadineHeat strokeEnvironmental heat stressEnvironmental exposure history; muscle rigidity rareRapid or gradualHydrationActive coolingMalignant hyperthermiaGenetic instability of sarcoplasmic reticulum, causing massive calcium release after administration of triggering medicationOccurs after administration of inhalational anesthetic or succinylcholine; muscle rigiditySudden, provoked by administration of anestheticStop anestheticHydrationActive coolingDantroleneMAOIs,Monoamine oxidase inhibitors;SSRIs,selective serotonin reuptake inhibitors.

A careful and thorough drug history should be obtained. There is a significant overlap in the features of NMS and serotonin syndrome. The major difference is the presence of hyperreflexia in NMS and myoclonus in serotonin syndrome.

Reference 3

3.

Elsevier ClinicalKey Clinical Overview

Diagnosis Table Title: Signs and symptoms of neuroleptic malignant syndrome, serotonin syndrome, and malignant hyperthermia. Table Citation: Data from Gillman PK: The serotonin syndrome and its treatment. J Psychopharmacol. 13(1):100-9, 1999; Gillman K: Serotonin Toxicity. PsychoTropical Research website. Accessed March 18, 2021. https://psychotropical.info/serotonin-toxicity; Wappler F et al: Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth. 87(5):794-8, 2001; and Malignant Hyperthermia. In: ToxED [database online]. Elsevier; 2012. http://www.toxed-ip.com/ToxEdView.aspx?id=596585#. Table Heads: Clinical features| Neuroleptic malignant syndrome| Serotonin syndrome| Malignant hyperthermia Table Rows: Triggering agent| Neuroleptic| Proserotonergic agent| Succinylcholine or inhaled anesthetic Onset| Slow (hours to days)| Fast (minutes to hours)| Very fast to fact (minutes to hours) Duration| Long (days to weeks)| Short (1-2 days)| Short (1-3 days) Agitation| Sometimes| Yes| No Confusion| Yes| Sometimes| Unusual Hyperactivity| No| Yes| No Bradykinesia/stupor| Yes| No| Unusual Myoclonus| No| Yes| No Shivering| No| Yes/sometimes| No Tremor| Sometimes| Yes| No Pupils| Mid-sized| Large| Not specific Hyperreflexia| No| Yes (especially lower extremities)| No Rigidity| Severe| Sometimes| Severe

Follow up questions